株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の癌補助療法薬剤市場規模、シェア、動向分析:治療クラス別(G-CSF、ビスフォスフォネート、制吐薬、オピオイド、NSAID、ESA)、地域別、セグメント予測(2019~2026年)

Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And Segment Forecasts, 2019 - 2026

発行 Grand View Research, Inc. 商品コード 820533
出版日 ページ情報 英文 110 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.62円で換算しております。
Back to Top
世界の癌補助療法薬剤市場規模、シェア、動向分析:治療クラス別(G-CSF、ビスフォスフォネート、制吐薬、オピオイド、NSAID、ESA)、地域別、セグメント予測(2019~2026年) Cancer Supportive Care Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (G-CSFs, Bisphosphonates, Antiemetics, Opioids, NSAIDs, ESAs), By Region, And Segment Forecasts, 2019 - 2026
出版日: 2019年06月27日 ページ情報: 英文 110 Pages
概要

世界の癌補助療法薬剤市場規模は今後CAGR1.0%で拡大し、2026年までに229億米ドルに達すると予測されています。癌の補助療法では、症状の予防や管理、癌の副作用とその治療に焦点が当てられます。

当レポートでは、世界の癌補助療法薬剤市場について調査し、市場の動向とセグメント別動向、地域別予測、市場に参入する企業のプロファイルについてまとめています。

第1章 調査方法と範囲

第2章 エグゼクティブサマリー

第3章 市場変動、動向、範囲

  • 市場見通し
  • 浸透および成長見通しマッピング
  • 製品パイプライン分析
  • 破壊的薬剤の臨床プロファイル
  • 法規制の枠組み
  • 市場動向
  • 特許失効分析
  • 市場分析ツール

第4章 薬剤クラス別市場

  • 定義と範囲
  • 市場シェア分析
  • セグメント概要
  • 市場規模、予測、動向分析
    • G-CSF
    • エリスロポエチン刺激剤(ESA)
    • 制吐薬
    • ビスフォスフォネート
    • オピオイド
    • NSAIDその他

第5章 地域別市場分析

  • 市場シェア分析
  • 地域別市場概要
  • SWOT分析
    • 北米
    • 欧州
    • アジア太平洋地域
    • ラテンアメリカ
    • 中東・アフリカ
  • 市場規模と予測、動向分析

第6章 競合分析

  • 近年の発展と影響分析
  • ベンダー環境
  • 主要企業プロファイル
図表

List of Tables

  • Table 1 List of Abbreviation
  • Table 2 Cancer supportive care market - Therapeutic classes
  • Table 3 Cancer supportive care R&D pipeline overview
  • Table 4 Product profile: RN624 (tanezumab)
  • Table 5 Product profile: Rolontis
  • Table 6 Product profile: NEPA IV (Fosnetupitant and palonosetron fixed combination)
  • Table 7 Product profile: Anamorelin
  • Table 8 Product profile: HTX-011
  • Table 9 Product profile: Myelo001
  • Table 10 Most prevalent cancers using chemotherapy and/or radiation therapy as a treatment
  • option in the U.S. (2016)
  • Table 11 Patent expiry analysis
  • Table 12 Major products- G-CSF
  • Table 13 Major products- Erythropoietin stimulating agents
  • Table 14 Major products- Antiemetics
  • Table 15 Major products- Bisphosphonates
  • Table 16 Major products- Opioids and non-opioid
  • Table 17 Product Portfolio: Epogen (epoetin alfa)
  • Table 18 Product Portfolio: Neupogen (filgrastim)
  • Table 19 Product Portfolio: Aranesp (darbepoetin alfa)
  • Table 20 Product Portfolio: Neulasta (pegfilgrastim)
  • Table 21 Product Portfolio: Xgeva (denosumab)
  • Table 22 Product Portfolio: Emend (aprepitant)
  • Table 23 Product Portfolio: Procrit/ Eprex (epoetin alfa)
  • Table 24 Product Portfolio: Sustol (granisetron)
  • Table 25 Product Portfolio: Cinvanti (aprepitant)
  • Table 26 Product Portfolio: Zometa (zolederonic acid)
  • Table 27 Product Portfolio: Zarxio (filgrastim biosimilar)
  • Table 28 Product Portfolio: Varubi (rolapitant)
  • Table 29 Product Portfolio: NeoRecormon (epoetin beta)
  • Table 30 Product Portfolio: Aloxi (palonosetron)

List of Figures

  • Fig. 1 Cancer supportive care drugs market segmentation
  • Fig. 2 Cancer supportive care market snapshot
  • Fig. 3 Parent market outlook
  • Fig. 4 Ancillary market outlook
  • Fig. 5 Penetration & growth prospect mapping
  • Fig. 6 Reimbursement of cancer medicines (2016)
  • Fig. 7 Cancer supportive care drugs market driver impact
  • Fig. 8 Cancer supportive care drugs: market restraint impact
  • Fig. 9 Cancer supportive care drugs: Porter's Analysis
  • Fig. 10 Cancer supportive care drugs market: Drug class outlook key takeaways
  • Fig. 11 Drug class market share analysis (2018 & 2026)
  • Fig. 12 Cancer supportive care drugs market: Type movement analysis
  • Fig. 13 G-CSFs market, 2015 - 2026 (USD Million)
  • Fig. 14 ESAs market, 2015 - 2026 (USD Million)
  • Fig. 15 Antiemetics market, 2015 - 2026 (USD Million)
  • Fig. 16 Bisphosphonates market, 2015 - 2026 (USD Million)
  • Fig. 17 Opioids market, 2015 - 2026 (USD Million)
  • Fig. 18 NSAIDs and others market, 2015 - 2026 (USD Million)
  • Fig. 19 Regional market place, 2015 - 2026 (USD Million)
  • Fig. 20 Regional market share analysis (2018 & 2026)
  • Fig. 21 Regional market dashboard
  • Fig. 22 North America cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 23 Europe cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 24 Asia Pacific cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 25 Latin America cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 26 Middle East & Africa cancer supportive care drugs market, SWOT analysis, by Factor
  • Fig. 27 North America cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 28 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 29 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 30 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 31 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 32 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 33 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 34 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 35 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 36 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 37 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 38 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 39 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 40 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 41 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 42 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 43 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 44 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 45 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 46 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 47 Middle East & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 48 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 49 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 50 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)
  • Fig. 51 Heat map analysis, by key market participants
  • Fig. 52 Key company market share analysis, 2018
目次
Product Code: GVR-2-68038-529-8

The global cancer supportive care drugs market size is projected to reach USD 22.9 billion by 2026, as per a new report by Grand View Research, Inc. It is expected to progress at a CAGR of 1.0% over the forecast period. Supportive care in cancer focuses on prevention and management of symptoms and side-effects associated with cancer and its treatment.

Key side effects caused by cancer treatment include anemia, neutropenia, nausea and vomiting, pain, and bone metastasis. Rise in the number of people suffering from the effects of anti-cancer therapies will drive the market, globally. The higher efficacy of supportive care drugs, such as colony stimulating factors (G-CSFs), opioid analgesics, erythropoietins, and antiemetic drugs, among others is anticipated to drive growth of the global cancer supportive care drugs market. High efficiency of these drugs in controlling the adverse effects of cancer and its treatment is projected to drive the demand in near future.

G-CSFs and ESAs therapeutic classes are witnessing a fundamental shift from biologics to biosimilars. The market for cancer pain, chemotherapy induced nausea and vomiting, and cancer induced bone diseases will grow significantly during the forecast period, due to new product launches and high unmet needs. The cancer pain market is estimated to witness a shift from opioids to non-opioids therapies. The shift will be backed by patent loss, high mortality, addiction, and major safety issues associated with narcotic agents.

Further key findings from the report suggest:

  • Some of the key market players are Amgen, Merck, Novartis, Johnson & Johnson, Roche, Helsinn Healthcare, Heron Pharma, Tesaro, and Purdue Pharma. Amgen led the global cancer supportive care market in 2018, capturing over 30% market share
  • By therapeutic class, the global ESAs market for CIA was valued at USD 1,838 million in 2018 and is expected to decline with a CAGR of 6.0% over the forecast period. The biologics segment is anticipated to lose its market share due to patent expiration of major brands such as Epogen
  • North America led the cancer supportive care drugs market in 2018 and is expected to maintain its position during the forecast period
  • Asia Pacific is expected to witness lucrative growth over the forecast period, owing to improvements in healthcare infrastructure and increasing government initiatives
  • Late stage pipeline products include non-opioids such as Tanezumab and HTX-011. Newer immunotherapies directed against PD-1 ligands and PD-L1 proteins have shown to be more effective with a superior safety profile

Table of Contents

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation
  • 1.2 Research Methodology
  • 1.3 Research Scope and Assumptions
  • 1.4 List to Data Sources
  • 1.5 List of Abbreviations

Chapter 2 Executive Summary

  • 2.1 Market Summary

Chapter 3 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Related/ Ancillary Market Outlook
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Product Pipeline Analysis, by Stage
  • 3.4 Clinical Profiles of Disruptive Drugs
  • 3.5 Regulatory Framework
  • 3.6 Market Dynamics
    • 3.6.1 Market Driver Analysis
      • 3.6.1.1 Growing cancer prevalence and increase in number of people receiving chemotherapy
      • 3.6.1.2 Large number of side effects associated with the cancer treatment
      • 3.6.1.3 Fundamental shift from branded biologics to biosimilar domination in cancer associated treatment
    • 3.6.2 Market Restraint Analysis
      • 3.6.2.1 Rising popularity of targeted therapies for the treatment of cancer in developed countries
      • 3.6.2.2 Unmet needs in cancer supportive care
      • 3.6.2.3 Safety issues associated with supportive care agents
  • 3.7 Patent Expiry Analysis
  • 3.8 Cancer Supportive Care Drugs Market: Market Analysis Tools
    • 3.8.1 Industry Analysis - Porter's
    • 3.8.2 major deals & strategic alliances analysis
      • 3.8.2.1 Joint Ventures
      • 3.8.2.2 Mergers & Acquistions
      • 3.8.2.3 Licensing & Partnership
      • 3.8.2.4 technology collaborations
    • 3.8.3 MARKET Dynamics and Brand STRATEGIES

Chapter 4 Cancer Supportive Care Drugs Market: Segment Analysis, by Drug Class, 2015 - 2026 (USD Million)

  • 4.1 Definitions & Scope
  • 4.2 Drug Class Market Share Analysis, 2018 & 2026
  • 4.3 Segment Dashboard
  • 4.4 Market Size & Forecasts and Trend Analysis, 2015 to 2026 for the following
    • 4.4.1 G-CSFs
      • 4.4.1.1 G-CSFs market, 2015 - 2026 (USD Million)
    • 4.4.2 Erythropoietin Stimulating Agents (ESA)
      • 4.4.2.1 Erythropoietin Stimulating Agents market, 2015 - 2026 (USD Million)
    • 4.4.3 Antiemetics
      • 4.4.3.1 Antiemetics market, 2015 - 2026 (USD Million)
    • 4.4.4 Bisphosphonates
      • 4.4.4.1 Bisphosphonates market, 2015 - 2026 (USD Million)
    • 4.4.5 Opioids
      • 4.4.5.1 opioids market, 2015 - 2026 (USD Million)
    • 4.4.6 NSAIDs and Others
      • 4.4.6.1 NSAIDs and Others market, 2015 - 2026 (USD Million)

Chapter 5 Cancer Supportive Care Drugs Market: Regional Market Analysis

  • 5.1 Regional Market Share Analysis, 2018 & 2026
  • 5.2 Regional Market Dashboard
  • 5.3 SWOT Analysis, by Factor (Political & Legal, Economic and Technological)
    • 5.3.1 North america
    • 5.3.2 Europe
    • 5.3.3 Asia pacific
    • 5.3.4 Latin America
    • 5.3.5 Middle east & africa
  • 5.4 Market Size & Forecasts, Estimates and Trend Analysis, 2018 to 2026
  • 5.5 North America
    • 5.5.1 North america cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.1.1 U.S.
      • 5.5.1.2 U.S. cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.1.3 Canada
      • 5.5.1.4 Canada cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.2 Europe cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.1 U.K.
      • 5.5.2.2 U.K. cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.3 Germany
      • 5.5.2.4 Germany cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.5 France
      • 5.5.2.6 France cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.7 Italy
      • 5.5.2.8 Italy cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.2.9 Spain
      • 5.5.2.10 Spain cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.3 Asia Pacific cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.1 CHINA
      • 5.5.3.2 China cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.3 India
      • 5.5.3.4 India cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.5 Japan
      • 5.5.3.6 Japan cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.7 Thailand
      • 5.5.3.8 Thailand cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.3.9 South Korea
      • 5.5.3.10 South Korea cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.4 Latin America cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.1 Brazil
      • 5.5.4.2 Brazil cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.3 Mexico
      • 5.5.4.4 Mexico cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.5 Argentina
      • 5.5.4.6 Argentina cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.4.7 Colombia
      • 5.5.4.8 Colombia cancer supportive care drugs market, 2015 - 2026 (USD Million)
    • 5.5.5 Middle east & Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.5.1 South Africa
      • 5.5.5.2 South Africa cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.5.3 Saudi Arabia
      • 5.5.5.4 Saudi Arabia cancer supportive care drugs market, 2015 - 2026 (USD Million)
      • 5.5.5.5 UAE
      • 5.5.5.6 UAE cancer supportive care drugs market, 2015 - 2026 (USD Million)

Chapter 6 Cancer Supportive Care Drugs Market - Competitive Analysis

  • 6.1 Recent Developments & Impact analysis, by key market participants
  • 6.2 Company Categorization
    • 6.2.1 Market Leader
    • 6.2.2 Key innovators
    • 6.2.3 Emerging Players
      • 6.2.3.1 Pfizer (Hospira)
      • 6.2.3.2 Heron Therapeutics
      • 6.2.3.3 Spectrum Pharmaceuticals
      • 6.2.3.4 Myelo Therapeutics
  • 6.3 Vendor Landscape
    • 6.3.1 Key Customers
    • 6.3.2 Key Company market share analysis, 2018
  • 6.4 Key Companies Profiled
    • 6.4.1 Amgen Inc.
      • 6.4.1.1 Company overview
      • 6.4.1.2 Financial Performance
      • 6.4.1.3 product benchmarking
      • 6.4.1.4 recent developments
    • 6.4.2 Merck & Co.
      • 6.4.2.1 Company Overview
      • 6.4.2.2 Financial Performance
      • 6.4.2.3 Product benchmarking
      • 6.4.2.4 Recent developments
    • 6.4.3 Johnson & Johnson SeRvices, Inc.
      • 6.4.3.1 Company Overview
      • 6.4.3.2 Financial Performance
      • 6.4.3.3 Product benchmarking
      • 6.4.3.4 Recent developments
    • 6.4.4 Heron Therapeutics, Inc.
      • 6.4.4.1 Company Overview
      • 6.4.4.2 Financial Performance
      • 6.4.4.3 Product benchmarking
      • 6.4.4.4 Recent developments
    • 6.4.5 NOVARTIS AG
      • 6.4.5.1 Company Overview
      • 6.4.5.2 Financial Performance
      • 6.4.5.3 Product benchmarking
      • 6.4.5.4 Recent developments
    • 6.4.6 TESARO, Inc.
      • 6.4.6.1 Company Overview
      • 6.4.6.2 Financial Performance
      • 6.4.6.3 Product benchmarking
      • 6.4.6.4 Recent developments
    • 6.4.7 F. Hoffmann-La Roche AG
      • 6.4.7.1 Company Overview
      • 6.4.7.2 Financial Performance
      • 6.4.7.3 Product benchmarking
      • 6.4.7.4 Recent developments
    • 6.4.8 HELSINN Healthcare SA
      • 6.4.8.1 Company Overview
      • 6.4.8.2 Product benchmarking
      • 6.4.8.3 Recent developments
Back to Top